[SCHEDULE 13G] Stoke Therapeutics, Inc. Passive Investment Disclosure (>5%)
Stoke Therapeutics: BVF may be deemed ~5.6% owner
The reported percentages use 64,526,242 Stoke shares outstanding as of July 30, 2026, and several ownership positions are attributed through shared voting power.
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Stoke Therapeutics, Inc. (STOK) is the issuer whose common stock is covered by a Schedule 13G reporting beneficial ownership by several investment funds and related entities. As of the close of business on September 30, 2026, Biotechnology Value Fund, L.P. beneficially owned 1,866,761 shares, Biotechnology Value Fund II, L.P. 1,404,263 shares, and Biotechnology Value Trading Fund OS LP 261,006 shares. BVF Partners L.P., BVF Inc. and Mark N. Lampert, a director and officer of BVF Inc., each may be deemed to beneficially own 3,608,968 shares, approximately 5.6%; BVF GP Holdings LLC may be deemed to beneficially own 3,271,024 shares, approximately 5.1%. The 3,608,968-share figure includes 76,938 shares held in the Partners Managed Account. The reporting persons disclose shared voting and dispositive power and disclaim beneficial ownership of certain shares attributed to others.
Key Figures
Biotechnology Value Fund shares beneficially owned:1,866,761 sharesBiotechnology Value Fund II shares beneficially owned:1,404,263 sharesBiotechnology Value Trading Fund OS shares beneficially owned:261,006 shares+4 more
7 metrics
Biotechnology Value Fund shares beneficially owned1,866,761 sharesAs of the close of business on September 30, 2026
Biotechnology Value Fund II shares beneficially owned1,404,263 sharesAs of the close of business on September 30, 2026
Biotechnology Value Trading Fund OS shares beneficially owned261,006 sharesAs of the close of business on September 30, 2026
Shares attributed to BVF Partners L.P., BVF Inc. and Mark N. Lampert3,608,968 sharesMay be deemed beneficially owned; approximately 5.6% as of September 30, 2026
Shares attributed to BVF GP Holdings LLC3,271,024 sharesMay be deemed beneficially owned; approximately 5.1% as of September 30, 2026
Partners Managed Account shares76,938 sharesIncluded in the 3,608,968 shares attributed to BVF Partners L.P.
Shares outstanding64,526,242 sharesAs of July 30, 2026; basis for the reported ownership percentages
"disclaims beneficial ownership of the Shares beneficially owned by BVF"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Shared Voting Powerfinancial
"Shared Voting Power 3,608,968.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
Shared Dispositive Powerfinancial
"Shared Dispositive Power 3,608,968.00"
Partners Managed Accountfinancial
"including 76,938 Shares held in the Partners Managed Account"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many STOK shares did the three funds report owning?
As of the close of business on September 30, 2026, Biotechnology Value Fund, L.P. beneficially owned 1,866,761 shares, Biotechnology Value Fund II, L.P. 1,404,263 shares, and Biotechnology Value Trading Fund OS LP 261,006 shares.
What percentage of STOK did Mark N. Lampert report owning?
Mark N. Lampert, a director and officer of BVF Inc., may be deemed to beneficially own 3,608,968 shares, approximately 5.6%, as of the close of business on September 30, 2026. BVF Partners L.P. and BVF Inc. may also be deemed to beneficially own the same shares.
What share count was used to calculate STOK ownership percentages?
The percentages are based on 64,526,242 shares outstanding as of July 30, 2026, as reported in Stoke Therapeutics’ Quarterly Report on Form 10-Q.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Stoke Therapeutics, Inc.
(Name of Issuer)
Common Stock, $0.0001 par value per share
(Title of Class of Securities)
86150R107
(CUSIP Number)
09/23/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
86150R107
1
Names of Reporting Persons
BIOTECHNOLOGY VALUE FUND L P
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,866,761.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,866,761.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,866,761.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
2.9 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP Number(s):
86150R107
1
Names of Reporting Persons
BVF I GP LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,866,761.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,866,761.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,866,761.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
2.9 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
86150R107
1
Names of Reporting Persons
BIOTECHNOLOGY VALUE FUND II LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,404,263.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,404,263.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,404,263.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
2.2 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP Number(s):
86150R107
1
Names of Reporting Persons
BVF II GP LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,404,263.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,404,263.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,404,263.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
2.2 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
86150R107
1
Names of Reporting Persons
Biotechnology Value Trading Fund OS LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
CAYMAN ISLANDS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
261,006.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
261,006.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
261,006.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.4 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP Number(s):
86150R107
1
Names of Reporting Persons
BVF Partners OS Ltd.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
CAYMAN ISLANDS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
261,006.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
261,006.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
261,006.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.4 %
12
Type of Reporting Person (See Instructions)
CO
SCHEDULE 13G
CUSIP Number(s):
86150R107
1
Names of Reporting Persons
BVF GP HOLDINGS LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,271,024.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,271,024.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,271,024.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.1 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
86150R107
1
Names of Reporting Persons
BVF PARTNERS L P/IL
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,608,968.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,608,968.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,608,968.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.6 %
12
Type of Reporting Person (See Instructions)
IA, PN
SCHEDULE 13G
CUSIP Number(s):
86150R107
1
Names of Reporting Persons
BVF INC/IL
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,608,968.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,608,968.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,608,968.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.6 %
12
Type of Reporting Person (See Instructions)
CO
SCHEDULE 13G
CUSIP Number(s):
86150R107
1
Names of Reporting Persons
LAMPERT MARK N
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,608,968.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,608,968.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,608,968.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.6 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Stoke Therapeutics, Inc.
(b)
Address of issuer's principal executive offices:
45 WIGGINS AVENUE, BEDFORD, MA 01730
Item 2.
(a)
Name of person filing:
Biotechnology Value Fund, L.P. ("BVF")
BVF I GP LLC ("BVF GP")
Biotechnology Value Fund II, L.P. ("BVF2")
BVF II GP LLC ("BVF2 GP")
Biotechnology Value Trading Fund OS LP ("Trading Fund OS")
BVF Partners OS Ltd. ("Partners OS")
BVF GP Holdings LLC ("BVF GPH")
BVF Partners L.P. ("Partners")
BVF Inc.
Mark N. Lampert ("Mr. Lampert")
Each of the foregoing is referred to as a "Reporting Person" and collectively as the "Reporting Persons."
(b)
Address or principal business office or, if none, residence:
Biotechnology Value Fund, L.P.
44 Montgomery St., 40th Floor
San Francisco, California 94104
BVF I GP LLC
44 Montgomery St., 40th Floor
San Francisco, California 94104
Biotechnology Value Fund II, L.P.
44 Montgomery St., 40th Floor
San Francisco, California 94104
BVF II GP LLC
44 Montgomery St., 40th Floor
San Francisco, California 94104
Biotechnology Value Trading Fund OS LP
PO Box 309 Ugland House
Grand Cayman, KY1-1104
Cayman Islands
BVF Partners OS Ltd.
PO Box 309 Ugland House
Grand Cayman, KY1-1104
Cayman Islands
BVF GP Holdings LLC
44 Montgomery St., 40th Floor
San Francisco, California 94104
BVF Partners L.P.
44 Montgomery St., 40th Floor
San Francisco, California 94104
BVF Inc.
44 Montgomery St., 40th Floor
San Francisco, California 94104
Mark N. Lampert
44 Montgomery St., 40th Floor
San Francisco, California 94104
(c)
Citizenship:
Biotechnology Value Fund, L.P.
Delaware
BVF I GP LLC
Delaware
Biotechnology Value Fund II, L.P.
Delaware
BVF II GP LLC
Delaware
Biotechnology Value Trading Fund OS LP
Cayman Islands
BVF Partners OS Ltd.
Cayman Islands
BVF GP Holdings LLC
Delaware
BVF Partners L.P.
Delaware
BVF Inc.
Delaware
Mark N. Lampert
United States
(d)
Title of class of securities:
Common Stock, $0.0001 par value per share
(e)
CUSIP Number(s):
86150R107
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
As of the close of business on September 30, 2026, (i) BVF beneficially owned 1,866,761 shares of the Issuer's Common Stock, $0.0001 par value per share (the "Shares"), (ii) BVF2 beneficially owned 1,404,263 Shares and (iii) Trading Fund OS beneficially owned 261,006 Shares.
BVF GP, as the general partner of BVF, may be deemed to beneficially own the 1,866,761 Shares beneficially owned by BVF.
BVF2 GP, as the general partner of BVF2, may be deemed to beneficially own the 1,404,263 Shares beneficially owned by BVF2.
Partners OS, as the general partner of Trading Fund OS, may be deemed to beneficially own the 261,006 Shares beneficially owned by Trading Fund OS.
BVF GPH, as the sole member of each of BVF GP and BVF2 GP, may be deemed to beneficially own the 3,271,024 Shares beneficially owned in the aggregate by BVF and BVF2.
Partners, as the investment manager of BVF, BVF2 and Trading Fund OS, and the sole member of Partners OS, may be deemed to beneficially own the 3,608,968 Shares beneficially owned in the aggregate by BVF, BVF2 and Trading Fund OS and held in a certain Partners managed account (the "Partners Managed Account"), including 76,938 Shares held in the Partners Managed Account.
BVF Inc., as the general partner of Partners, may be deemed to beneficially own the 3,608,968 Shares beneficially owned by Partners.
Mr. Lampert, as a director and officer of BVF Inc., may be deemed to beneficially own the 3,608,968 Shares beneficially owned by BVF Inc.
The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of any Shares owned by another Reporting Person. BVF GP disclaims beneficial ownership of the Shares beneficially owned by BVF. BVF2 GP disclaims beneficial ownership of the Shares beneficially owned by BVF2. Partners OS disclaims beneficial ownership of the Shares beneficially owned by Trading Fund OS. BVF GPH disclaims beneficial ownership of the Shares beneficially owned by BVF and BVF2. Each of Partners, BVF Inc. and Mr. Lampert disclaims beneficial ownership of the Shares beneficially owned by BVF, BVF2 and Trading Fund OS and held in the Partners Managed Account, and the filing of this statement shall not be construed as an admission that any such person or entity is the beneficial owner of any such securities.
(b)
Percent of class:
The following percentages are based on 64,526,242 Shares outstanding as of July 30, 2026, which is the total number of Shares outstanding as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 3, 2026.
As of the close of business on September 30, 2026, (i) BVF beneficially owned approximately 2.9% of the outstanding Shares, (ii) BVF2 beneficially owned approximately 2.2% of the outstanding Shares, (iii) Trading Fund OS beneficially owned less than 1% of the outstanding Shares, (iv) BVF GP may be deemed to beneficially own approximately 2.9% of the outstanding Shares, (v) BVF2 GP may be deemed to beneficially own approximately 2.2% of the outstanding Shares, (vi) Partners OS may be deemed to beneficially own less than 1% of the outstanding Shares, (vii) BVF GPH may be deemed to beneficially own approximately 5.1% of the outstanding Shares, and (viii) each of Partners, BVF Inc. and Mr. Lampert may be deemed to beneficially own approximately 5.6% of the outstanding Shares (less than 1% of the outstanding Shares are held in the Partners Managed Account).
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
See Cover Pages Items 5-9.
(ii) Shared power to vote or to direct the vote:
See Cover Pages Items 5-9.
(iii) Sole power to dispose or to direct the disposition of:
See Cover Pages Items 5-9.
(iv) Shared power to dispose or to direct the disposition of:
See Cover Pages Items 5-9.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
BVF GPH, Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by BVF and BVF2. Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by Trading Fund OS and held in the Partners Managed Account.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.
See Exhibit 99.1.
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
BIOTECHNOLOGY VALUE FUND L P
Signature:
/s/ Mark N. Lampert
Name/Title:
Mark N. Lampert, Authorized Signatory
Date:
09/30/2026
BVF I GP LLC
Signature:
/s/ Mark N. Lampert
Name/Title:
Mark N. Lampert, Authorized Signatory
Date:
09/30/2026
BIOTECHNOLOGY VALUE FUND II LP
Signature:
/s/ Mark N. Lampert
Name/Title:
Mark N. Lampert, Authorized Signatory
Date:
09/30/2026
BVF II GP LLC
Signature:
/s/ Mark N. Lampert
Name/Title:
Mark N. Lampert, Authorized Signatory
Date:
09/30/2026
Biotechnology Value Trading Fund OS LP
Signature:
/s/ Mark N. Lampert
Name/Title:
Mark N. Lampert, Authorized Signatory
Date:
09/30/2026
BVF Partners OS Ltd.
Signature:
/s/ Mark N. Lampert
Name/Title:
Mark N. Lampert, Authorized Signatory
Date:
09/30/2026
BVF GP HOLDINGS LLC
Signature:
/s/ Mark N. Lampert
Name/Title:
Mark N. Lampert, Authorized Signatory
Date:
09/30/2026
BVF PARTNERS L P/IL
Signature:
/s/ Mark N. Lampert
Name/Title:
Mark N. Lampert, Authorized Signatory
Date:
09/30/2026
BVF INC/IL
Signature:
/s/ Mark N. Lampert
Name/Title:
Mark N. Lampert, Authorized Signatory
Date:
09/30/2026
LAMPERT MARK N
Signature:
/s/ Mark N. Lampert
Name/Title:
Mark N. Lampert
Date:
09/30/2026
Exhibit Information
99.1 - Joint Filing Agreement, September 30, 2026.
